H.C. Wainwright Keeps Cormedix (AMEX:CRMD) As “Buy”; Has Target Of $2.0000; Blackrock Municipal 2020 Term Trust (BKK) Has 1.07 Sentiment

May 23, 2018 - By Louis Casey


Cormedix Inc (AMEX:CRMD) had its stock rating noted as “Buy” by analysts at H.C. Wainwright. H.C. Wainwright currently has a $2.0000 target price per share on the $14.26M market cap company or 1,076.47% upside potential. This was released in an analyst note on Wednesday, 23 May.

Blackrock Municipal 2020 Term Trust (BKK) investors sentiment decreased to 1.07 in 2017 Q4. It’s down -0.57, from 1.64 in 2017Q3. The ratio fall, as 15 active investment managers increased and started new equity positions, while 14 cut down and sold their positions in Blackrock Municipal 2020 Term Trust. The active investment managers in our database now possess: 1.85 million shares, down from 2.02 million shares in 2017Q3. Also, the number of active investment managers holding Blackrock Municipal 2020 Term Trust in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 10 Increased: 8 New Position: 7.

Lehman Financial Resources Inc. holds 0.97% of its portfolio in BlackRock Municipal 2020 Term Trust for 125,060 shares. Walter & Keenan Financial Consulting Co Mi Adv owns 111,100 shares or 0.7% of their US portfolio. Moreover, Ronna Sue Cohen has 0.68% invested in the company for 63,571 shares. The New Jersey-based Roundview Capital Llc has invested 0.12% in the stock. Edge Wealth Management Llc, a New York-based fund reported 22,475 shares.

The stock increased 0.33% or $0.05 during the last trading session, reaching $15.17. About 59,069 shares traded or 85.03% up from the average. BlackRock Municipal 2020 Term Trust (BKK) has declined 4.11% since May 23, 2017 and is downtrending. It has underperformed by 15.66% the S&P500.

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.58, from 0.67 in 2017Q3. It is positive, as 3 investors sold CorMedix, Inc. shares while 5 reduced holdings. 3 funds opened positions while 7 raised stakes. 3.71 million shares or 11.19% less from 4.18 million shares in 2017Q3 were reported. Private Advisor Gru Ltd Liability Company reported 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). State Bank Of Mellon stated it has 62,604 shares. Hightower Advisors owns 37,188 shares. Tci Wealth Advisors owns 2,900 shares for 0% of their portfolio. Deutsche Financial Bank Ag, Germany-based fund reported 51,600 shares. Blackrock invested in 563,775 shares. 17,767 are owned by State Street Corp. Franklin Resources reported 0% stake. Taurus Asset Mgmt Lc invested 0% in CorMedix, Inc. (NYSEAMERICAN:CRMD). Washington Tru, a Rhode Island-based fund reported 24,750 shares. Thompson Davis And Incorporated invested in 2,000 shares or 0% of the stock. Virtu Ltd Llc reported 226,748 shares or 0.01% of all its holdings. Royal Commercial Bank Of Canada stated it has 0% of its portfolio in CorMedix, Inc. (NYSEAMERICAN:CRMD). Morgan Stanley accumulated 0% or 13,198 shares. Gru One Trading L P holds 0% or 88,548 shares.

The stock decreased 8.37% or $0.0159 during the last trading session, reaching $0.1741. About 898,399 shares traded. CorMedix, Inc. (AMEX:CRMD) has declined 88.81% since May 23, 2017 and is downtrending. It has underperformed by 100.36% the S&P500.

Among 2 analysts covering Cormedix (AMEX:CRMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cormedix has $7.50 highest and $300 lowest target. $5.75’s average target is 3202.70% above currents $0.1741 stock price. Cormedix had 5 analyst reports since March 17, 2016 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 10 report. Rodman & Renshaw maintained CorMedix, Inc. (NYSEAMERICAN:CRMD) rating on Thursday, March 17. Rodman & Renshaw has “Buy” rating and $7.50 target. As per Monday, April 2, the company rating was maintained by H.C. Wainwright. The stock of CorMedix, Inc. (NYSEAMERICAN:CRMD) has “Buy” rating given on Monday, September 25 by H.C. Wainwright. The firm has “Buy” rating given on Monday, October 16 by H.C. Wainwright.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $14.26 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News